Bristol-Myers Squibb selects CEO Giovanni Caforio as new chairman

Bristol-Myers Squibb selects CEO Giovanni Caforio as new chairman

“It is an honour to have the opportunity to build on the strong foundation established by [Andreotti],” Caforio remarked, adding “working with the talented leaders and employees of this company, I look forward to further advancing our BioPharma strategy, and delivering transformational medicines that make a difference in the lives of patients around the world.”

Caforio, who succeeded Andreotti as CEO, previously served as Bristol-Myers Squibb’s chief operating officer and chief commercial officer, joining the board of directors in 2014.

“Since becoming CEO last year, [Caforio] has demonstrated strong leadership and a commitment to the company’s patient-focused mission and culture of integrity and ethics,” commented Togo West, Jr., the board’s lead independent director, adding “[Caforio’s] depth of experience, knowledge and deep understanding of the industry make him the right person for the chairmanship.”

December 22, 2016 / Pharma News